Anticancer Therapies – Products

Life science specialists, AMSBIO, have made a new strategic investment to enhance the level of support to its sizeable and growing base of customers across the European Union.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.

After years of research and experience by our technicians, we successfully established the "Star Staining" site-specific labeling platform and developed a series of exclusive fluorescent-labeled proteins with "Star Standard" quality.

One of the more promising types of cancer immunotherapy involves engineering immune cells to recognize and attack cancer.

AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

Download this app note to discover immunoassay platforms that are consistent for your cell therapy and immunology development needs.

The utility and efficiency of the Octet® platform at characterizing covalent immune recruiter molecule function and their efficacy as modulators of protein proximity was demonstrated. Efficient in vitro validation further enables the potential acceleration of CIR translation to in vivo model validation and the clinic as a new class of synthetic tumor immunotherapeutic.